Longitudinal progression trajectory of GFR among patients with CKD.

BACKGROUND The traditional paradigm of glomerular filtration rate (GFR) progression in patients with chronic kidney disease (CKD) is a steady nearly linear decline over time. We describe individual GFR progression trajectories over 12 years of follow-up in participants in the African American Study of Kidney Disease and Hypertension (AASK). STUDY DESIGN Longitudinal observational study. SETTING & PARTICIPANTS 846 AASK patients with at least 3 years of follow-up and 8 GFR estimates. MEASUREMENTS Longitudinal GFR estimates from creatinine-based equations. PREDICTORS Patient demographic and clinical features. OUTCOMES Probability of a nonlinear trajectory and probability of a period of nonprogression calculated for each patient from a Bayesian model of individual estimated GFR (eGFR) trajectories. RESULTS 352 (41.6%) patients showed a > 0.9 probability of having either a nonlinear trajectory or a prolonged nonprogression period; in 559 (66.1%), the probability was > 0.5. Baseline eGFR > 40 mL/min/1.73 m2 and urine protein-creatinine ratio < 0.22 g/g were associated with a higher likelihood of a nonprogression period. 74 patients (8.7%) had both a substantial period of stable or increasing eGFR and a substantial period of rapid eGFR decrease. LIMITATIONS Clinical trial population; absence of direct GFR measurements. CONCLUSIONS In contrast to the traditional paradigm of steady GFR progression over time, many patients with CKD have a nonlinear GFR trajectory or a prolonged period of nonprogression. These findings highlight the possibility that stable kidney disease progression can accelerate and, conversely, provide hope that CKD need not be relentlessly progressive. These results should encourage researchers to identify time-dependent factors associated with periods of nonprogression and other desirable trajectories.

[1]  J. Lewis,et al.  Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  M. Kutner,et al.  Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). , 2003, Journal of the American Society of Nephrology : JASN.

[3]  N W Shock,et al.  Longitudinal Studies on the Rate of Decline in Renal Function with Age , 1985, Journal of the American Geriatrics Society.

[4]  G. Beck,et al.  Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. , 1997, Kidney international.

[5]  Black Mm Letter: Cryostat sections in immunological studies of cancer. , 1973 .

[6]  G. Beck,et al.  The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .

[7]  N. Madias,et al.  Serum creatinine and renal function. , 1988, Annual review of medicine.

[8]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[10]  Keith C. Norris,et al.  The rationale and design of the AASK cohort study. , 2003, Journal of the American Society of Nephrology : JASN.

[11]  W. Mitch,et al.  A SIMPLE METHOD OF ESTIMATING PROGRESSION OF CHRONIC RENAL FAILURE , 1976, The Lancet.

[12]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[13]  R. Garrick Baseline Predictors of Renal Disease Progression in the African American Study of Hypertension and Kidney Disease , 2008 .

[14]  Ciprian M. Crainiceanu,et al.  Bayesian Analysis for Penalized Spline Regression Using WinBUGS , 2005 .

[15]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.